58 schemes that included a coverage with evidence development component, 25 that included a conditional treatment continuation component, 35 that included a performance-linked reimbursement component, and 37 that included a patient level financial utilization component. Each type of scheme addresses fundamental uncertainties that exist when products enter the market. There has been a continued upward trend in terms of total schemes adopted per year and the number of countries with performance-based schemes in place. Despite the continued enthusiasm, challenges persist including those related to: 1) the cost and burden of implementation; 2) the need for consistent processes for scheme development, data collection, reporting, and evaluation; and 3) negotiating follow-on agreements after scheme initiation. Furthermore, the challenges faced differ by country, health system, and product. CONCLUSIONS: There is continued enthusiasm in many countries for using performance-based schemes for new medical products. Given the interest to date and the potential to meet the goals of interested stakeholders, these schemes may become a common element in health care coverage and reimbursement. However, significant challenges persist, and future studies are needed regarding the attitudes and perceptions of various stakeholders as well as evaluating the results and experiences with the schemes implemented thus far. 
PHP148 GLOBAL PHARMACEUTICAL RISK-SHARING AGREEMENT TRENDS IN 2010 AND 2011
Ando G 
OBJECTIVES:
With payors increasingly looking at ways of cutting pharmaceutical reimbursement costs, pharmaceutical companies need to consider creative solutions to market access for new compounds. The objective of this research was to examine the most recent global trends for 2010 and 2011 in pharmaceutical risksharing agreements, which are now a critical part of market access strategies in many countries. METHODS: Secondary research was conducted examining reimbursement decisions around the world, with a special focus on Australia, Belgium, Canada, China, France, Germany, Hungary, Italy, The Netherlands, New Zealand, Poland, Spain, UK and United States. This was supplemented by primary research with payors, government agencies and HTA organisations through interviews in native languages to understand the role which risk-sharing agreements have -or have not -played in their respective markets. RESULTS: Forty-five new risk-sharing agreements were found under the period of review (January 2010-May 2011), nearly double the total for 2009. Of the new agreements, the majority were financebased agreements, though there were six new examples of performance-based agreements. 40% of the new agreements were concluded with the UK's NICE, whilst Australia and Italy remain other important markets in this area. However, a significant number of newer countries are beginning to see these agreements, including Belgium, Hungary, Poland and New Zealand, and interest is widening in emerging markets. Around half of the agreements were in the oncology area, but there are signs that risk-sharing is becoming increasingly prominent in other therapeutic areas, including blood disease, mental health, pain treatment, immunology, ophthalmology and cardiovascular care. CONCLUSIONS: Risk-sharing agreements are a reality for pharmaceutical companies in many key markets, and need at least to be considered as an alternative market access strategy in certain therapeutic areas. 
PHP149 PERCEPTION OF PHARMACEUTICAL COMPANIES ON THE DRUG PRICE-VOLUME NEGOTIATION IN SOUTH KOREA

OBJECTIVES:
In Korea, although drug price has continuously decreased due to many price reduction mechanisms, the volume has been increasing. Because this risen volume is considered a main contributor of increasing pharmaceutical expenditure, the government adopted price-volume negotiation in 2006. This study attempted to analyze the status of price-volume (PV) negotiation and identify problems and the solutions to improve the price-volume negotiation. METHODS: The comprehensive questionnaire was designed based on Korea price negotiation guideline and validated by three pilot interviewers. It consisted of the status, awareness, satisfaction, problems/solutions. Pharmaceutical company's people involved in market access were interviewed face-to-face. The response rate was 80% (nϭ34). Multinational and local company accounted for 59% and 41%, respectively. RESULTS: Most important factors for PV negotiation were budget impact and price from the Korean PV formula. 69% of 16 PV cases were derived from the price calculated by PV formula and only 42% reached the consensus on budget impact because of different data sources. Most respondents agreed with the objective of the risk-sharing system but the overall satisfaction was significantly low, 1.9 out of 5-point scale. Main reasons are unpredictability of selecting PV product, discreditable NHIC data and non-transparency of the negotiation process. Also, 76.5% of respondents was against PV negotiation because of the government's unnecessary intervention and concerns on weakening the pharmaceutical industry. Especially, respondents worried about profit deterioration due to duplicated price reduction. In response, they suggested the advanced PV model with a more specific PV inclusion criteria and the choice between price reduction and pay-back. Additionally, generic promotion and pay-back system activation to contain the drug expenditure are preferred over price-volume negotiation.
CONCLUSIONS:
The price-volume negotiation in Korea must be improved to motivate the pharmaceutical industry through adopting their opinions on advanced PV model which includes pay-back. 
PHP150 PHARMACEUTICAL PRICING UNDER UNCERTAINTY: RISK-SHARING CONTRACTS
OBJECTIVES:
Pharmaceutical pricing decisions are adopted in a context of uncertainty with regard to the efficacy and safety of the drug as well as to their budgetary implications. Traditionally, pharmaceutical firms have received a fixed price per unit sold regardless of health outcomes and sales volume. This pricing policy tends to increase health budgets and may restrict the access to pharmaceutical innovations for patients. Recently, health authorities have begun to use risk-sharing contracts based on health outcomes to cope with the aforementioned problem. In this paper, we carry out a theoretical modelling of the risk-sharing contracts, emphasizing the variables and parameters that are relevant in the relationship between health authorities and pharmaceutical firms. METHODS: We have elaborated a theoretical model that describes the interaction between a pharmaceutical firm and a public health authority using a two-stage game. In the first stage, the health authority chooses the pricing policy, either paying to the firm for treated patient or for cured patient, and in the second stage, the firm, given the pricing policy and the prescribing behaviour of the physicians, selects the price that maximizes its expected profits. We solve the game by backward induction, using the subgame perfect equilibrium as the solution concept. RESULTS: Risk-sharing contracts are not always optimal in terms of social welfare. Their optimality depends on the parameters of the problem, being conditioned by the prescribing behaviour of the physicians, the efficacy of the drug and the monitoring costs. We characterize the parametric regions for which each pricing policy is socially optimal. CONCLUSIONS: Before using risk-sharing contracts, their convenience must be addressed for each particular case. As a necessary condition, the existence of objective quantitative health indicators is required. Otherwise, it is difficult to implement the pricing policy only based on cured patients.
PHP151 EVIDENCE ON THE IMPACT OF MANAGED ENTRIES ON PAYERS, PATIENTS, MANUFACTURERS, AND HEALTH CARE WORKERS
Ferrario A, Nicod E, Kanavos P London School of Economics and Political Science, London, England, UK OBJECTIVES: Managed entries (MEs) are innovative pricing and reimbursement agreements aiming to share the risk related to the introduction of new, high-cost drugs between the payer and the manufacturer. This study aims to review evidence on the impact of MEs on payer, patients, manufacturer, and health care workers and to analyse emerging trends in managed entries at international level. METHODS: A systematic literature review (grey and peer-reviewed) was performed complemented by search of health technology assessment agency's websites and selective interviews with decision makers in key European countries. RESULTS: Evidence exists of improved cost-effectiveness and lower drug price following the implementation of coverage with evidence development in Sweden. Data from France shows that price-volume agreements led to rebates totalling around 3% of the total drugs bill. Evidence from Italy shows that authorization with a risk-sharing agreement was associated with more rapid patient access in comparison to authorization without such an agreement. It is unclear whether managed entries A360 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
